Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T21:52:57.288Z.
Calculation as of: 2026-10-06T21:52:57.288Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ed0d84ebe65fc765338e7baf7154c4548c52c7814b601df66b93f049f622236d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Prime Medicine, Inc.
Market Cap
$632.16M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$630.63M
Operating Cash Flow Yield
N/A
TTM Avg
2.08%
3Y Avg
1.21%
5Y Avg
1.21%
Market Cap
$634.30M
Operating Cash Flow Yield
5.27%
TTM Avg
2.97%
3Y Avg
2.97%
5Y Avg
4.09%
Market Cap
$638.20M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$619.15M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$611.57M
Operating Cash Flow Yield
N/A
TTM Avg
0.02%
3Y Avg
0.02%
5Y Avg
0.02%
Market Cap
$656.59M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$657.89M
Operating Cash Flow Yield
0.05%
TTM Avg
0.05%
3Y Avg
0.05%
5Y Avg
0.05%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prime Medicine, Inc. (PRME) | $632.16M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $630.63M | N/A | 2.08% | 1.21% | 1.21% |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 5.27% | 2.97% | 2.97% | 4.09% |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | N/A | N/A | N/A | N/A |
| SOPHiA GENETICS S.A. (SOPH)vs › | $619.15M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | N/A | 0.02% | 0.02% | 0.02% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | 0.05% | 0.05% | 0.05% | 0.05% |
| Annexon, Inc. (ANNX)vs › | $660.29M | N/A | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 31.05% | 16.53% | 24.40% | 19.97% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
